EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Proteinuria with extended VEGF inhibitor therapy in RAS-mutant metastatic colorectal cancer: incidence, interruptions, and exploratory survival analysis

Daichi Watanabe, Hironori Fujii, Yuto Miura, Misato Kani, Wakana Chikaishi, Jesse Yu Tajima, Akitaka Makiyama, Yunami Yamada, Koichi Ohata, Chiemi Hirose, Hirotoshi Iihara, Ryo Kobayashi und 2 weitere

International Journal of Colorectal Disease · 04.08.2026 · 41 (1)

DOI: 10.1007/s00384-026-05210-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Colorectal Disease, online erschienen am 04.08.2026. Verfasst von Daichi Watanabe und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Gifu University Hospital, Gifu, Japan. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Proteinuria, Vascular Endothelial Growth Factor A, Mutation. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gifu University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Vascular endothelial growth factor inhibitors (VEGFIs) are essential for the treatment of metastatic colorectal cancer (mCRC). Given the ineffectiveness of epidermal growth factor receptor inhibitors in managing RAS-mutant mCRC, long-term VEGFI therapy is often required; however, it is associated with an increased risk of proteinuria. As the use of VEGFI in later-line mCRC treatment has become more prevalent, proteinuria has emerged as a critical dose-limiting toxicity. However, its effect on the treatment outcomes remains unclear. This study examined the incidence of proteinuria during extended VEGFI use and its effect on overall survival (OS) in RAS-mutant mCRC.

Methods

This single-center retrospective study analyzed patients with RAS-mutant stage IV mCRC treated with first-line VEGFIs at Gifu University Hospital. Proteinuria incidence was estimated using the Kaplan–Meier method. OS from a 12-month landmark was compared according to the occurrence of dipstick proteinuria 2+ or greater within the first year using Cox regression.

Results

Among 185 patients, the Kaplan–Meier cumulative incidence of dipstick proteinuria 2+ or greater was 11%, 37%, and 45% at 1, 2, and 3 years, respectively. Of 123 patients in the 12-month landmark cohort, 13 had early-onset proteinuria. The age- and sex-adjusted HR for subsequent mortality was 1.81 (95% CI 0.84–3.86; p = 0.128).

Conclusions

Proteinuria accumulated during extended VEGFI therapy. Early-onset proteinuria may be associated with poorer subsequent OS, although the wide confidence interval precludes a definitive conclusion. These findings underscore the importance of careful proteinuria monitoring during long-term VEGFI treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsProteinuriaVascular Endothelial Growth Factor AMutationAngiogenesis Inhibitorsras ProteinsHumansFemaleIncidenceMaleNeoplasm MetastasisAgedMiddle AgedKaplan-Meier EstimateSurvival AnalysisProportional Hazards ModelsAged, 80 and over

Stichwörter der Autor:innen

Angiogenesis inhibitorsBevacizumabColorectal neoplasmsProteinuriaTreatment outcome

Substanzen

Vascular Endothelial Growth Factor AAngiogenesis Inhibitorsras Proteins

Autor:innen und Institutionen

  • Department of Pharmacy, Gifu University Hospital, Gifu, Japan.
  • Innovative and Clinical Research Promotion Center, Gifu University Hospital, Gifu, Japan.
  • Department of Pharmacy, Gifu University Hospital, Gifu, Japan. fujii.hironori.u5@f.gifu-u.ac.jp.
  • Laboratory of Advanced Medical Pharmacy, Gifu Pharmaceutical University, Gifu, Japan.
  • Department of Surgical Oncology, Gifu University Graduate School of Medicine, Gifu, Japan.
  • Cancer Center, Gifu University Hospital, Gifu, Japan.

Förderung

  • Gifu University

Zitieren

APA

Watanabe, D., Fujii, H., Miura, Y., Kani, M., Chikaishi, W., Tajima, J. Y., Makiyama, A., Yamada, Y., Ohata, K., Hirose, C., Iihara, H., Kobayashi, R., Matsuhashi, N., & Suzuki, A. (2026). Proteinuria with extended VEGF inhibitor therapy in RAS-mutant metastatic colorectal cancer: incidence, interruptions, and exploratory survival analysis. International Journal of Colorectal Disease, 41(1). https://doi.org/10.1007/s00384-026-05210-x

Vancouver

Watanabe D, Fujii H, Miura Y, Kani M, Chikaishi W, Tajima JY, et al. Proteinuria with extended VEGF inhibitor therapy in RAS-mutant metastatic colorectal cancer: incidence, interruptions, and exploratory survival analysis. International Journal of Colorectal Disease. 2026;41(1). doi:10.1007/s00384-026-05210-x

BibTeX
@article{Watanabe2026,
  author = {Watanabe, Daichi and Fujii, Hironori and Miura, Yuto and Kani, Misato and Chikaishi, Wakana and Tajima, Jesse Yu and Makiyama, Akitaka and Yamada, Yunami and Ohata, Koichi and Hirose, Chiemi and Iihara, Hirotoshi and Kobayashi, Ryo and Matsuhashi, Nobuhisa and Suzuki, Akio},
  title = {Proteinuria with extended VEGF inhibitor therapy in RAS-mutant metastatic colorectal cancer: incidence, interruptions, and exploratory survival analysis},
  journal = {International Journal of Colorectal Disease},
  year = {2026},
  volume = {41},
  number = {1},
  doi = {10.1007/s00384-026-05210-x}
}
Kostenlos starten →